Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for post-ECT cognition in elderly patients with major depressive disorder
IRCT20151122025191N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of memantine in major depressive disorder (MDD) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Cognition score according to Addenbrooke's Cognitive Examination and Depression score according to Geriatric Depression Scale. Started Oct 2020; status: completed.
02
Drugs
memantine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20151122025191N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151122025191N2.